G1899高丽红参提取物粉对急性COVID - 19感染的治疗作用：随机、双盲、安慰剂对照试验

IF 6.8 2区医学 Q1 CHEMISTRY, MEDICINAL

Journal of Ginseng Research Pub Date : 2025-04-24 DOI:10.1016/j.jgr.2025.04.007

In-Ho Seo , Byoungjin Park , Heejung Kim , Seok-Jae Heo , Dong-Hyuk Jung

{"title":"G1899高丽红参提取物粉对急性COVID - 19感染的治疗作用：随机、双盲、安慰剂对照试验","authors":"In-Ho Seo , Byoungjin Park , Heejung Kim , Seok-Jae Heo , Dong-Hyuk Jung","doi":"10.1016/j.jgr.2025.04.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>In this study, we investigated the therapeutic potential effects of G1899 Korean Red Ginseng Extract Powder(G1899) on long COVID in a general population using flow cytometry and follow-up by questionnaire.</div></div><div><h3>Methods</h3><div>We conducted a 12-week clinical pilot study on 220 COVID19 patients who were recently infected. The study was completed by 108 participants in the G1899 group and 108 participants in the placebo group. Participants were randomized 1:1 to the G1899 and placebo groups. We evaluated the long COVID by questionnaire including GAD-7, FSS and BFI-K at baseline and 12 weeks. To investigate the changes in the levels of CD4/CD8 T cell ratio and regulatory T cell population, multicolor flow cytometry was performed.</div></div><div><h3>Results</h3><div>The G1899 group showed significantly chronic fatigue symptoms relieving compared with placebo group at 12 weeks in women. The CD4/CD8 ratio increased significantly in the G1899 group, rising from 1.71 (95 % CI: 1.35–2.07) at Visit 1 to 2.31 (95 % CI: 1.83–2.78) at Visit 4 (p = 0.0029). Unlike the G1899 group, there was a significant reduction in the Treg population, from 2.02 % at Visit 1–1.22 % at Visit 4 (p = 0.0005) in the placebo group.</div></div><div><h3>Conclusion</h3><div>These findings suggest that G1899 has beneficial effects on the amelioration of long COVID symptoms, with more prominent effects observed in women. Although the changes in Treg population were not statistically significant in the G1899 group, the significant reduction observed in the placebo group suggests a potential protective effect of G1899 against Treg depletion.</div></div>","PeriodicalId":16035,"journal":{"name":"Journal of Ginseng Research","volume":"49 4","pages":"Pages 470-477"},"PeriodicalIF":6.8000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effects of G1899 Korean red ginseng extract powder on long COVID for acute COVID19 infection: A randomized, double-blind, placebo-controlled trial\",\"authors\":\"In-Ho Seo , Byoungjin Park , Heejung Kim , Seok-Jae Heo , Dong-Hyuk Jung\",\"doi\":\"10.1016/j.jgr.2025.04.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>In this study, we investigated the therapeutic potential effects of G1899 Korean Red Ginseng Extract Powder(G1899) on long COVID in a general population using flow cytometry and follow-up by questionnaire.</div></div><div><h3>Methods</h3><div>We conducted a 12-week clinical pilot study on 220 COVID19 patients who were recently infected. The study was completed by 108 participants in the G1899 group and 108 participants in the placebo group. Participants were randomized 1:1 to the G1899 and placebo groups. We evaluated the long COVID by questionnaire including GAD-7, FSS and BFI-K at baseline and 12 weeks. To investigate the changes in the levels of CD4/CD8 T cell ratio and regulatory T cell population, multicolor flow cytometry was performed.</div></div><div><h3>Results</h3><div>The G1899 group showed significantly chronic fatigue symptoms relieving compared with placebo group at 12 weeks in women. The CD4/CD8 ratio increased significantly in the G1899 group, rising from 1.71 (95 % CI: 1.35–2.07) at Visit 1 to 2.31 (95 % CI: 1.83–2.78) at Visit 4 (p = 0.0029). Unlike the G1899 group, there was a significant reduction in the Treg population, from 2.02 % at Visit 1–1.22 % at Visit 4 (p = 0.0005) in the placebo group.</div></div><div><h3>Conclusion</h3><div>These findings suggest that G1899 has beneficial effects on the amelioration of long COVID symptoms, with more prominent effects observed in women. Although the changes in Treg population were not statistically significant in the G1899 group, the significant reduction observed in the placebo group suggests a potential protective effect of G1899 against Treg depletion.</div></div>\",\"PeriodicalId\":16035,\"journal\":{\"name\":\"Journal of Ginseng Research\",\"volume\":\"49 4\",\"pages\":\"Pages 470-477\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ginseng Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1226845325000570\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ginseng Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1226845325000570","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

本研究采用流式细胞术和问卷随访法，探讨G1899高丽红参提取物粉（G1899）对普通人群长冠肺炎的潜在治疗作用。方法对近期感染的220例新冠肺炎患者进行为期12周的临床先导研究。该研究由108名G1899组参与者和108名安慰剂组参与者完成。参与者按1:1的比例随机分为G1899组和安慰剂组。在基线和12周时，我们通过问卷调查包括GAD-7、FSS和BFI-K来评估长期COVID。采用多色流式细胞术观察CD4/CD8 T细胞比值及调节性T细胞群的变化。结果与安慰剂组相比，G1899组在12周时明显缓解了妇女的慢性疲劳症状。G1899组CD4/CD8比值显著升高，从第1次随访时的1.71 （95% CI: 1.35-2.07）上升到第4次随访时的2.31 (95% CI: 1.83-2.78) （p = 0.0029）。与G1899组不同，安慰剂组的Treg人群显著减少，从第1次访问时的2.02%减少到第4次访问时的1.22% （p = 0.0005）。结论G1899对改善COVID - 19患者长期症状有有益作用，且对女性疗效更显著。尽管在G1899组中Treg数量的变化没有统计学意义，但在安慰剂组中观察到的显著减少表明G1899对Treg消耗有潜在的保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The effects of G1899 Korean red ginseng extract powder on long COVID for acute COVID19 infection: A randomized, double-blind, placebo-controlled trial

Background

In this study, we investigated the therapeutic potential effects of G1899 Korean Red Ginseng Extract Powder(G1899) on long COVID in a general population using flow cytometry and follow-up by questionnaire.

Methods

We conducted a 12-week clinical pilot study on 220 COVID19 patients who were recently infected. The study was completed by 108 participants in the G1899 group and 108 participants in the placebo group. Participants were randomized 1:1 to the G1899 and placebo groups. We evaluated the long COVID by questionnaire including GAD-7, FSS and BFI-K at baseline and 12 weeks. To investigate the changes in the levels of CD4/CD8 T cell ratio and regulatory T cell population, multicolor flow cytometry was performed.

Results

The G1899 group showed significantly chronic fatigue symptoms relieving compared with placebo group at 12 weeks in women. The CD4/CD8 ratio increased significantly in the G1899 group, rising from 1.71 (95 % CI: 1.35–2.07) at Visit 1 to 2.31 (95 % CI: 1.83–2.78) at Visit 4 (p = 0.0029). Unlike the G1899 group, there was a significant reduction in the Treg population, from 2.02 % at Visit 1–1.22 % at Visit 4 (p = 0.0005) in the placebo group.

Conclusion

These findings suggest that G1899 has beneficial effects on the amelioration of long COVID symptoms, with more prominent effects observed in women. Although the changes in Treg population were not statistically significant in the G1899 group, the significant reduction observed in the placebo group suggests a potential protective effect of G1899 against Treg depletion.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Ginseng Research CHEMISTRY, MEDICINAL-INTEGRATIVE & COMPLEMENTARY MEDICINE

CiteScore

11.40

自引率

9.50%

发文量

111

审稿时长

6-12 weeks

期刊介绍： Journal of Ginseng Research (JGR) is an official, open access journal of the Korean Society of Ginseng and is the only international journal publishing scholarly reports on ginseng research in the world. The journal is a bimonthly peer-reviewed publication featuring high-quality studies related to basic, pre-clinical, and clinical researches on ginseng to reflect recent progresses in ginseng research. JGR publishes papers, either experimental or theoretical, that advance our understanding of ginseng science, including plant sciences, biology, chemistry, pharmacology, toxicology, pharmacokinetics, veterinary medicine, biochemistry, manufacture, and clinical study of ginseng since 1976. It also includes the new paradigm of integrative research, covering alternative medicinal approaches. Article types considered for publication include review articles, original research articles, and brief reports. JGR helps researchers to understand mechanisms for traditional efficacy of ginseng and to put their clinical evidence together. It provides balanced information on basic science and clinical applications to researchers, manufacturers, practitioners, teachers, scholars, and medical doctors.